+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
PTC Therapeutics - logo

PTC Therapeutics is a biopharmaceutical company that focuses on the development and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The company's lead product candidate is Translarna (ataluren), which is for the treatment of of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is currently in Phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey.

From
From
Market Spotlight: Duchenne Muscular Dystrophy (DMD) - Product Thumbnail Image

Market Spotlight: Duchenne Muscular Dystrophy (DMD)

  • Report
  • February 2020
  • 56 Pages
From
From
Limb Girdle Muscular Dystrophy (LGMD) - Pipeline Insight, 2020 - Product Thumbnail Image

Limb Girdle Muscular Dystrophy (LGMD) - Pipeline Insight, 2020

  • Drug Pipelines
  • February 2020
  • 106 Pages
From
From
Duchenne Muscular Dystrophy - Pipeline Review, H1 2020 - Product Thumbnail Image

Duchenne Muscular Dystrophy - Pipeline Review, H1 2020

  • Drug Pipelines
  • February 2020
  • 381 Pages
From
Becker Muscular Dystrophy - Pipeline Review, H1 2020 - Product Thumbnail Image

Becker Muscular Dystrophy - Pipeline Review, H1 2020

  • Drug Pipelines
  • February 2020
  • 75 Pages
From
Muscular Dystrophy - Pipeline Review, H2 2019 - Product Thumbnail Image

Muscular Dystrophy - Pipeline Review, H2 2019

  • Drug Pipelines
  • December 2019
  • 233 Pages
From
From
Loading Indicator
adroll